Lirafugratinib hydrochloride is under clinical development by Relay Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lirafugratinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lirafugratinib hydrochloride overview
RLY-4008 is under development for the treatment of metastatic solid tumors like intrahepatic cholangiocarcinoma and breast cancer. It is administered by oral route. The drug candidate acts by targeting fibroblast growth factor receptor 2 (FGFR2). It is being developed based on Dynamo platform.
It was under development for the treatment of gastric cancer, endometrial cancer.
Relay Therapeutics overview
Relay Therapeutics is a biotechnology company that develops therapies for multiple diseases. The company’s technology enables the rational allosteric drug discovery process to design better drugs. It leverages insights from protein motion to develop its products. Relay Therapeutics brings together scientific advances including biophysics, chemistry, structural biology, computation, and biology to enable new approaches for therapeutic intervention in disease. Its research focuses on the discovery and development of oncology therapeutics. The company partners with various healthcare companies. Relay Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Lirafugratinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.